Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug

Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug
ShareXFacebook

(MedPage Today) -- SAN JUAN, PUERTO RICO -- As many as 70% of patients with advanced/metastatic HER2-expressing endometrial cancer (EC) responded to an investigational antibody-drug conjugate (ADC), according to phase II data. Response to trastuzumab...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

AI and the New Folie a Deux
MedPage Today

AI and the New Folie a Deux

(MedPage Today) -- Artificial intelligence (AI) is rapidly becoming part of our patients' inner lives. In medical practice, we are accustomed to asking about relationships, stressors, substances, and sleep. Increasingly, however, we must also ask...

Read more →
Advertisement